Concert is developing innovative medicines with unique therapeutic properties to address the needs of patients with chronic diseases.

CTP-692

A promising first-in-class approach to broaden the scope of treating schizophrenia

CTP-543

A drug candidate for alopecia areata, a disease with no currently-approved treatments

LATEST NEWS

Oct 29, 2020
Concert Pharmaceuticals Presents CTP-543 Data from Long-Term Extension Study in Alopecia Areata During Late-Breaking Session at EADV Congress

Oct 29, 2020
Concert Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 5, 2020

© 2020 Concert Pharmaceuticals. All rights reserved.
HOME | SITEMAP | CONTACT | TERMS OF USE | PRIVACY POLICY
Back to Top